Evidence map›Paper›PMID 27283598›Full record

ArticleDiagnostic pathology2016

The long non-coding RNA CCAT2 is up-regulated in ovarian cancer and associated with poor prognosis.

Shuying Huang, Cheng Qing, Zikun Huang, Yuanfang Zhu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diagnostic pathology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 2 pooled it
6.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 2 syntheses or guidelines pooled it, 81 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Shuying HuangDepartment of Obstetrics and Gynecology, the First Affiliated Hospital of Nanchang University, Nanchang, 330006, Jiangxi, China.
Cheng QingIntensive Care Unit, the First Affiliated Hospital of Nanchang University, Nanchang, 330006, Jiangxi, China.
Zikun HuangDepartment of Clinical Laboratory, the First Affiliated Hospital of Nanchang University, Nanchang, 330006, Jiangxi, China.
Yuanfang ZhuDepartment of Obstetrics and Gynecology, the First Affiliated Hospital of Nanchang University, Nanchang, 330006, Jiangxi, China. zyf20151207@163.com.ORCID http://orcid.org/0000-0002-4242-582X
Nanchang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOvarian cancer is a malignant tumor with a poor prognosis. Accumulating evidence demonstrates that long non-coding RNAs (lncRNAs) are emerging regulators in cancer biology, and can be used as potential biomarkers for cancer diagnosis, prognosis and targeted therapy. The lncRNA CCAT2 (colon cancer associated transcript 2) was recently shown to be involved in several cancers; however, its role in ovarian cancer remains unknown.

methodsExpression levels of the lncRNA CCAT2 in ovarian cancer tissues, adjacent normal tissues, and cell lines were assessed by quantitative real-time PCR. Then, the associations of CCAT2 expression levels with clinicopathological features and prognosis were evaluated. In addition, CCAT2 functions in tumor progression and invasion were further determined by siRNA-induced CCAT2 silencing in vitro.

resultsExpression levels of the lncRNA CCAT2 in ovarian cancer tissues and cell lines were significantly higher compared with values obtained for adjacent non-tumor tissues and normal ovarian epithelial cells. Interestingly, higher CCAT2 expression levels were associated with a shorter overall survival (P = 0.006) and disease-free survival (P = 0.001) in ovarian cancer patients. In addition, CCAT2 expression was positively correlated with FIGO stage (P = 0.002), tumor grade (P = 0.006) and distant metastasis (P < 0.001). Moreover, CCAT2 knockdown in ovarian cancer cells markedly suppressed cell proliferation, migration, and invasion.

conclusionsThe lncRNA CCAT2 is a novel factor involved in ovarian cancer progression, and constitutes a potential prognostic biomarker and therapeutic target for patients with ovarian cancer.

Indexed as

Gene Expression Regulation, NeoplasticBiomarkers, TumorCell Line, TumorCell MovementCell ProliferationDisease ProgressionFemaleHumansKaplan-Meier EstimateMiddle AgedNeoplasm InvasivenessOvarian NeoplasmsPrognosisRNA, Long NoncodingRNA, Small InterferingUp-RegulationBiomarkers, Tumorlong non-coding RNA CCAT2, humanRNA, Long NoncodingRNA, Small InterferingColon cancer associated transcript 2LncRNAsOvarian cancerPrognosis

Identifiers

PMID27283598
PMCPMC4901397
OpenAlexW2411053091

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.